Plus Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on Plus Therapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date Plus Therapeutics Inc Strategy Report
- Understand Plus Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Plus Therapeutics Inc (Plus Therapeutics), formerly Cytori Therapeutics Inc is a developmental-stage pharmaceutical company, which focuses on the discovery, development, and manufacturing of complex and innovative treatments for patients with cancer and other life-threatening diseases. The company’s pipeline of candidate drug products includes Doceplus, a patented albumin-stabilized Pegylated liposomal formulation of docetaxel; Doxoplus, a complex, injectable, generic Pegylated liposomal formulation of doxorubicin; BMEDA-chelated rhenium nanoliposome (RNL); and a co-encapsulated, doxorubicin and rhenium nanoliposome (DRNL). It uses a proprietary nanotechnology platform to reformulate and improve conventional chemotherapeutics. Plus Therapeutics is headquartered in Irvine, Texas, the US.
Plus Therapeutics Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
Doceplus- Relapsed Small Cell Lung Cancer |
RNL- Recurrent Glioblastoma, Ovarian Carcinomatosis, Leptomeningeal Carcinomatosis, Breast Cancer, and Cancers of Head, Neck and Liver |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In December, the company entered into an agreement with K2bio for the creation of novel diagnostics for tumor cell and molecular biomarker studies in cerebrospinal fluid (csf). |
2023 | Contracts/Agreements | In September, the company entered into an agreement with Biocept to exclusively license Biocept's CNSide, a CSF-based tumor cell capture and enumeration platform, for patients receiving CNS radiotherapy. |
2023 | Contracts/Agreements | In May, the company and Piramal Pharma Solutions expanded their partnership to produce additional cGMP liposome intermediate drug products. |
Competitor Comparison
Key Parameters | Plus Therapeutics Inc | Bayer AG | VBI Vaccines Inc | MediciNova Inc | Notable Labs Ltd |
---|---|---|---|---|---|
Headquarters | United States of America | Germany | United States of America | United States of America | United States of America |
City | Austin | Leverkusen | Cambridge | La Jolla | Foster City |
State/Province | Texas | Nordrhein-Westfalen | Massachusetts | California | California |
No. of Employees | 20 | 99,723 | 131 | 13 | 16 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Richard J. Hawkins | Chairman | Executive Board | 2018 | 75 |
Marc H. Hedrick, M.D. | Chief Executive Officer; Director; President | Executive Board | 2014 | 60 |
Andrew Sims | Chief Financial Officer; Vice President | Senior Management | 2020 | 50 |
Norman LaFrance | Senior Vice President; Chief Medical Officer | Senior Management | 2021 | 75 |
Russ Havranek | Vice President - Corporate Strategy and New Product Planning | Senior Management | 2014 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer